Results 121 to 130 of about 15,343 (151)
Some of the next articles are maybe not open access.
Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review
Mini-Reviews in Medicinal Chemistry, 2023Abstract: Polo-like kinase 4 (PLK4), a serine/threonine kinase, is a member of the PLK family. As a key regulator of the cell cycle, PLK4 controls centrosome duplication and mitosis. Abnormal PLK4’s function can induce centrosome amplification, leading to tumorigenesis, therefore, PLK4 has been regarded as a promising target for cancer therapy, and ...
Chenzhong Liao +4 more
openaire +2 more sources
Therapeutic potential of targeting polo-like kinase 4
European Journal of Medicinal ChemistryPolo-like kinase 4 (PLK4), a highly conserved serine/threonine kinase, masterfully regulates centriole duplication in a spatiotemporal manner to ensure the fidelity of centrosome duplication and proper mitosis. Abnormal expression of PLK4 contributes to genomic instability and associates with a poor prognosis in cancer.
Qian Lei +8 more
openaire +2 more sources
Abstract 2736: Regulation of cytokinesis by polo-like kinase 4
Cancer Research, 2016Abstract Introduction. The serine/threonine mitotic kinase, polo-like kinase 4 (PLK4), is known to play a critical role in centrosome duplication in preparation for cell division. Based on our preliminary observations with a PLK4 kinase inhibitor, we investigated the possibility that PLK4 may also play a role in regulation of cytokinesis.
Michael F. Press +8 more
openaire +1 more source
Harnessing Structure Prediction of Polo‐Like Kinase 4 for Drug Repurposing
CytoskeletonABSTRACT Polo‐like kinase 4 (PLK4) is a centrosome‐specific kinase aberrantly expressed in cancers. Drugs inhibiting its catalytic kinase domain are under clinical phase‐1/2 trials in patients with different leukemia types. However, the kinase domain of PLK4 shows structural similarity with other kinases.
Harshita Kasera, Priyanka Singh
openaire +2 more sources
The Human Polo-like Kinase 4 is a Regulator of Centrosome Duplication
2006Polo-like kinase 4 (Plk4), also known as Snk/Fnk-akin kinase (Sak), is the most structurally divergent member of the Polo-like kinase family (Fode et al., 1994; Leung et al., 2002) and has been associated with cell proliferation (Fode et al., 1994). Most importantly, Plk4-/- mice were found to be embryonically lethal whereas heterozygous Plk+/- mice ...
openaire +2 more sources
Abstract 2544: Overexpression of the Polo-like kinase 4 (PLK4) contribute to tumor metastasis
Cancer Research, 2019Abstract The Polo-like kinase 4 (PLK4) is an important mitotic kinase that lies at the head of centriole duplication pathway. Aberration of PLK4's level in cancer cell often results in supernumery centrosome. PLK4 transcripts was upregulated in a number of cancers including breast, colon gastric and lung cancer, and PLK4 ...
Yeung Sai Fung, Yick Pang Ching
openaire +1 more source
Cancer Letters
Glioblastoma (GBM) is an extremely aggressive tumor associated with a poor prognosis that impacts the central nervous system. Increasing evidence suggests an inherent association between glucose metabolism dysregulation and the aggression of GBM. Polo-like kinase 4 (PLK4), a highly conserved serine/threonine protein kinase, was found to relate to ...
Bo, Wang +9 more
openaire +2 more sources
Glioblastoma (GBM) is an extremely aggressive tumor associated with a poor prognosis that impacts the central nervous system. Increasing evidence suggests an inherent association between glucose metabolism dysregulation and the aggression of GBM. Polo-like kinase 4 (PLK4), a highly conserved serine/threonine protein kinase, was found to relate to ...
Bo, Wang +9 more
openaire +2 more sources
Cancer Letters
Vasculogenic mimicry (VM), which involved the formation of vascular-like structures by highly invasive tumor cells, had been identified as one of the mechanisms contributing to resistance against anti-angiogenic therapy in patients with glioblastoma (GBM).
Bo Wang +5 more
openaire +2 more sources
Vasculogenic mimicry (VM), which involved the formation of vascular-like structures by highly invasive tumor cells, had been identified as one of the mechanisms contributing to resistance against anti-angiogenic therapy in patients with glioblastoma (GBM).
Bo Wang +5 more
openaire +2 more sources
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications
Journal of Drug Targeting, 2021Ilma Shakeel +2 more
exaly